Sugi Predict

Sugi Predict / Compounds / SCHEMBL7103183

SCHEMBL7103183

SCHEMBL7103183

Oc1cc(O)n2ncnc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.46
▸ ENPP1 P22413 1/20 0.41
▸ KDM4E B2RXH2 8/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MAPK1 P28482 4/20 0.38
▸ HPGD P15428 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ EGLN2 Q96KS0 1/20 0.36
▸ POLB P06746 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10887539 0.80 ALDH1A1 (0.43) ALDH1A1ENPP1KDM4ESMN1; SMN2MAPK1
SCHEMBL5146977 0.80 ALDH1A1 (0.67) ALDH1A1ENPP1KDM4ESMN1; SMN2MAPK1
SCHEMBL272835 0.80 ALDH1A1 (0.67) ALDH1A1ENPP1KDM4ESMN1; SMN2MAPK1
SCHEMBL5164814 0.79 ALDH1A1 (0.65) ALDH1A1ENPP1KDM4ESMN1; SMN2MAPK1
SCHEMBL8421909 0.79 ALDH1A1 (0.65) ALDH1A1ENPP1KDM4ESMN1; SMN2MAPK1
SCHEMBL19194460 0.76 EGLN2 (0.55) ALDH1A1ENPP1KDM4EMAPK1HPGD
SCHEMBL31728547 0.76 PDE2A (0.40) ALDH1A1ENPP1KDM4ESMN1; SMN2HPGD
SCHEMBL5145474 0.76 ALDH1A1 (0.43) ALDH1A1ENPP1KDM4ESMN1; SMN2MAPK1
SCHEMBL5051039 0.76 ALDH1A1 (0.40) ALDH1A1ENPP1KDM4ESMN1; SMN2MAPK1
SCHEMBL20266759 0.76 ALDH1A1 (0.43) ALDH1A1ENPP1KDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 — — EP disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
EP-4308230-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 — — EP disclosed
CN-112538083-B Aromatic ring penta aromatic heterocyclic micromolecule organic compound targeting BCL6, derivative thereof and application thereof 华东师范大学 2023-04-28 — — CN disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 — — WO disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 — — WO disclosed
CN-112538083-A Aromatic ring and five-membered aromatic heterocyclic micromolecule organic compound targeting BCL6, derivatives thereof and application thereof 华东师范大学 2021-03-23 — — CN disclosed
US-20170216295-A1 CCR9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2017-08-03 — — US disclosed
EP-0297397-A2 Preparation of diazo and azo compounds BAYER AG (DE) 1989-01-04 — — EP disclosed
EP-0273986-A1 PROCESS FOR PROCESSING SILVER HALIDE COLOR PHOTOGRAPHIC MATERIALS AND COLOR DEVELOPER FOR USE IN SAID PROCESS KONICA CORPORATION (JP) 1988-07-13 — — EP disclosed
EP-0228914-A2 Method of processing lightsensitive silver halide color photographic material KONICA CORPORATION (JP) 1987-07-15 — — EP disclosed
US-4628082-A Derivatives of azobarbituric acid or salts or complexes thereof BAYER AKTIENGESELLSCHAFT (DE) 1986-12-09 — — US disclosed
US-4622391-A ORGANIC PIGMENTS BAYER AKTIENGESELLSCHAFT (DE) 1986-11-11 — — US disclosed
EP-0074515-B1 AZO DERIVATIVES OF BARBITURIC ACID, THEIR SOLID SOLUTIONS, INSERTION COMPOUNDS AND INTERCALATION COMPOUNDS BAYER AG (DE) 1986-08-20 — — EP disclosed
EP-0073463-B1 INSERTION COMPOUNDS, INTERCALATION COMPOUNDS AND SOLID SOLUTIONS OF COLOURED METALLIC ORGANIC DERIVATIVES BAYER AG (DE) 1985-10-23 — — EP disclosed
EP-0093306-A1 Methods for the preparation of azo compounds, and azo compounds BAYER AG (DE) 1983-11-09 — — EP disclosed
EP-0074515-A1 Azo derivatives of barbituric acid, their solid solutions, insertion compounds and intercalation compounds BAYER AG (DE) 1983-03-23 — — EP disclosed
EP-0073463-A1 Insertion compounds, intercalation compounds and solid solutions of coloured metallic organic derivatives BAYER AG (DE) 1983-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 ALDH1A1 3026/4885ENPP1 2283/4885KDM4E 796/4885
US-20170216295-A1 CCR9 ANTAGONIST COMPOUNDS CCR9, CCR1, CCR10 ALDH1A1 1264/4885ENPP1 1752/4885KDM4E 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.